Healthcare [ 7/13 ] | Drug Manufacturers - Specialty & Generic [ 75/163 ]
NASDAQ | Common Stock
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -2.88 Decreased by -928.57% | -1.17 Decreased by -146.15% |
| Mar 15, 24 | 1.65 Increased by +1.28 K% | -1.19 Increased by +238.66% |
| Nov 9, 23 | -4.64 Decreased by -4.12 K% | -3.78 Decreased by -22.75% |
| Aug 11, 23 | -7.23 Decreased by -14.36 K% | -4.61 Decreased by -56.83% |
| May 12, 23 | -0.28 Decreased by -86.67% | -0.19 Decreased by -47.37% |
| Mar 8, 23 | -0.14 Increased by +6.67% | -0.11 Decreased by -27.27% |
| Nov 14, 22 | -0.11 Increased by +94.50% | -0.29 Increased by +62.07% |
| Aug 12, 22 | -0.05 Increased by +96.35% | -0.34 Increased by +85.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 7.90 M Decreased by -9.53% | -10.44 M Decreased by -39.57% | Decreased by -132.10% Decreased by -54.27% |
| Dec 31, 23 | 10.60 M Increased by +4.46% | 3.53 M Increased by +226.61% | Increased by +33.28% Increased by +221.21% |
| Sep 30, 23 | 8.88 M Increased by +105.44% | -6.34 M Decreased by -147.16% | Decreased by -71.43% Decreased by -20.31% |
| Jun 30, 23 | 5.85 M Increased by +31.21% | -9.84 M Decreased by -239.22% | Decreased by -168.21% Decreased by -206.10% |
| Mar 31, 23 | 8.73 M Decreased by -4.74% | -7.48 M Increased by +48.45% | Decreased by -85.63% Increased by +45.88% |
| Dec 31, 22 | 10.14 M Increased by +10.65% | -2.79 M Increased by +80.80% | Decreased by -27.45% Increased by +82.65% |
| Sep 30, 22 | 4.32 M Decreased by -0.28% | -2.57 M Increased by +83.97% | Decreased by -59.37% Increased by +83.93% |
| Jun 30, 22 | 4.46 M Decreased by -23.88% | 7.07 M Increased by +293.01% | Increased by +158.54% Increased by +353.55% |